Complete atrioventricular canal-left heart obstruction syndrome

Summary

Complete atrioventricular canal-left heart obstruction syndrome (MONDO:0020406) is a disease. A subtype of complete atrioventricular canal — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	complete atrioventricular canal-left heart obstruction syndrome
Mondo ID	MONDO:0020406
Orphanet	99066
GARD	0025160
Is cancer (heuristic)	no

Also known as: CAVC type A · CAVC-left heart obstruction syndrome · complete atrioventricular canal type A

Disease family

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › congenital heart disease › heart septal defect › familial atrioventricular septal defect › complete atrioventricular canal › complete atrioventricular canal-left heart obstruction syndrome

Related subtypes (2): complete atrioventricular canal-ventricle hypoplasia syndrome, complete atrioventricular canal-tetralogy of fallot syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.